Treatment Options in Non-alcoholic Fatty Liver Disease.
10.4166/kjg.2017.69.6.353
- Author:
Won KIM
1
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. drwon1@snu.ac.kr
- Publication Type:Review
- Keywords:
Nonalcoholic fatty liver disease;
Nonalcoholic steatohepatitis;
Fibrosis;
Pharmacotherapy
- MeSH:
Apoptosis;
Carcinoma, Hepatocellular;
Diet;
Drug Therapy;
Fatty Liver;
Fibrosis;
Hand;
Humans;
Inflammation;
Korea;
Non-alcoholic Fatty Liver Disease*;
Obesity;
Peroxisomes;
Prevalence;
Stress, Physiological;
Weight Loss
- From:The Korean Journal of Gastroenterology
2017;69(6):353-358
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The prevalence of non-alcoholic fatty liver disease (NAFLD) has sharply increased over the past several decades in Korea. In most cases of NAFLD, metabolic stress and cellular apoptosis are often driven by metabolic abnormality, eventually leading to inflammation and fibrosis . Along with a dramatic surge in the obesity epidemic, 10–20% of NAFLD patients ultimately progress to non-alcoholic steatohepatitis (NASH), a precursor to cirrhosis and hepatocellular carcinoma, as well as multi-organ systemic diseases. Currently, diet and exercise are chiefly recommended to achieve significant weight loss and improve metabolic dysfunction in patients with NAFLD. However, weight loss remains to be an elusive goal for both clinical practitioners and NAFLD patients. To date, although there has not been any proven pharmacotherapy against NAFLD, numerous promising pipelines with good target engagement are under development. Moreover, given the global landmark phase 3 trials using obeticholic acid (a farnesoid X receptor agonist, REGENERATE trial) and elafibranor (a dual peroxisome proliferator-activated receptor α/δ agonist, RESOLVE-IT trial), the era of specific target therapies focusing on molecular and metabolic pathogenesis of NASH and fibrosis is near at hand. In this paper, we briefly cover the current and future therapeutic options in patients with NAFLD across the entire spectrum of diseases.
